Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 15/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408483 | 1.00 | CCR2 (0.44) | CCR2CCR5CTSBCTSSCTSK | |
| SCHEMBL6408481 | 0.93 | DRD2 (0.41) | CCR2CCR5CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6415582 | 0.92 | CCR2 (0.47) | CCR2CCR5ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6409151 | 0.92 | CCR5 (0.44) | CCR2CCR5 | |
| SCHEMBL6409940 | 0.92 | CCR5 (0.42) | CCR2CCR5 | |
| SCHEMBL6413430 | 0.92 | CCR5 (0.41) | CCR5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6409540 | 0.91 | CCR2 (0.46) | CCR2CCR5ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6409363 | 0.91 | CCR2 (0.38) | CCR2CCR5CTSBCTSSCTSK | |
| SCHEMBL5249697 | 0.90 | DRD2 (0.40) | CCR2CCR5CTSBCTSSCTSK | |
| SCHEMBL6413530 | 0.90 | CCR2 (0.45) | CCR2CCR5ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR2 5/4885CCR5 4/4885CTSB 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.